These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

57 related items for PubMed ID: 6086859

  • 1. High titer of interferon (IFN)-neutralizing antibody in a patient with glioblastoma treated with IFN-alpha. Case report.
    Otsuka S, Handa H, Yamashita J.
    J Neurosurg; 1984 Sep; 61(3):591-3. PubMed ID: 6086859
    [Abstract] [Full Text] [Related]

  • 2. [rInterferon-alpha A (Ro 22-8181) therapy for patients with malignant brain tumors].
    Otsuka S, Yamashita J, Keyaki A, Handa H.
    Gan To Kagaku Ryoho; 1984 May; 11(5):1084-91. PubMed ID: 6326684
    [Abstract] [Full Text] [Related]

  • 3. Loss of interferon antibodies during prolonged continuous interferon-alpha 2a therapy in hairy cell leukemia.
    Steis RG, Smith JW, Urba WJ, Venzon DJ, Longo DL, Barney R, Evans LM, Itri LM, Ewel CH.
    Blood; 1991 Feb 15; 77(4):792-8. PubMed ID: 1704264
    [Abstract] [Full Text] [Related]

  • 4. Low incidence of neutralizing antibody formation to interferon-alpha 2b in human recipients.
    Dianzani F, Antonelli G, Amicucci P, Cefaro A, Pintus C.
    J Interferon Res; 1989 Sep 15; 9 Suppl 1():S33-6. PubMed ID: 2681442
    [Abstract] [Full Text] [Related]

  • 5. Detection and incidence of neutralizing antibodies to interferon-alpha-n1.
    Weck PK, Leventhal BG, Brand C, Finter NB.
    J Interferon Res; 1989 Sep 15; 9 Suppl 1():S37-43. PubMed ID: 2553830
    [Abstract] [Full Text] [Related]

  • 6. Formation of neutralizing antibodies against natural interferon-beta, but not against recombinant interferon-gamma during adjuvant therapy for high-risk malignant melanoma patients.
    Dummer R, Müller W, Nestle F, Wiede J, Dues J, Lechner W, Haubitz I, Wolf W, Bill E, Burg G.
    Cancer; 1991 May 01; 67(9):2300-4. PubMed ID: 1901514
    [Abstract] [Full Text] [Related]

  • 7. [Phase II study of recombinant leukocyte A interferon (Ro 22-8181) in malignant brain tumors].
    Gan To Kagaku Ryoho; 1985 Apr 01; 12(4):913-20. PubMed ID: 3885862
    [Abstract] [Full Text] [Related]

  • 8. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
    Ozer H, Gavigan M, O'Malley J, Thompson D, Dadey B, Nussbaum-Blumenson A, Snider C, Rudnick S, Ferraresi R, Norred S.
    J Biol Response Mod; 1983 Apr 01; 2(6):499-515. PubMed ID: 6607323
    [Abstract] [Full Text] [Related]

  • 9. Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha2 therapy.
    Antonelli G, Giannelli G, Currenti M, Simeoni E, Del Vecchio S, Maggi F, Pistello M, Roffi L, Pastore G, Chemello L, Dianzani F.
    Clin Exp Immunol; 1996 Jun 01; 104(3):384-7. PubMed ID: 9099919
    [Abstract] [Full Text] [Related]

  • 10. Interferon-alpha neutralizing antibodies in HIV and chronic HCV patients treated with natural-source human leukocyte-derived interferon-alpha n3.
    Zhao XX, Hua J, Smith T, Ferencz-Biro K, Liao MJ, Rashidbaigi A.
    Hum Antibodies; 1997 Jun 01; 8(3):129-36. PubMed ID: 9322083
    [Abstract] [Full Text] [Related]

  • 11. Sensitive antiproliferative neutralization assay for the detection of neutralizing IFN-alpha and IFN-beta antibodies.
    Prümmer O, Streichan U, Heimpel H, Porzsolt F.
    J Immunol Methods; 1994 May 02; 171(1):45-53. PubMed ID: 8176238
    [Abstract] [Full Text] [Related]

  • 12. Neutralization of interferon by antibody: appraisals of methods of determining and expressing the neutralization titer.
    Kawade Y, Watanabe Y.
    J Interferon Res; 1984 May 02; 4(4):571-84. PubMed ID: 6389723
    [Abstract] [Full Text] [Related]

  • 13. [Effect of human fibroblast interferon on malignant brain tumors].
    Nakamura O, Teramoto A, Yamamoto H, Ochiai C, Takakura K, Maruo K, Ueyama Y, Shimamura K.
    No To Shinkei; 1983 Sep 02; 35(9):905-11. PubMed ID: 6651989
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of neutralizing antibodies in patients treated with recombinant interferon-beta ser.
    Larocca AP, Leung SC, Marcus SG, Colby CB, Borden EC.
    J Interferon Res; 1989 Sep 02; 9 Suppl 1():S51-60. PubMed ID: 2809278
    [Abstract] [Full Text] [Related]

  • 15. Therapy-induced antibodies against the antiviral and antiproliferative effects of interferons in patients with chronic hepatitis C virus infection.
    Bálint E, Bakay M, Onody K, Farkas F, Horváth G, Tolvaj G, Dávid K, Horányi M, Béládi I.
    Acta Microbiol Immunol Hung; 2004 Sep 02; 51(3):359-69. PubMed ID: 15571075
    [Abstract] [Full Text] [Related]

  • 16. Antibodies to human leucocyte interferons in cancer patients.
    Trown PW, Kramer MJ, Dennin RA, Connell EV, Palleroni AV, Quesada J, Gutterman JU.
    Lancet; 1983 Jan 15; 1(8316):81-4. PubMed ID: 6129455
    [Abstract] [Full Text] [Related]

  • 17. [Interferon (IFN) therapy (recombinant IFN-alpha-2C or recombinant IFN-gamma) in metastasized hypernephroma].
    Kuzmits R, Scheithauer W, Ludwig H, Flener R.
    Acta Med Austriaca; 1985 Jan 15; 12(5):129-34. PubMed ID: 3938590
    [Abstract] [Full Text] [Related]

  • 18. [Histopathologic evaluation of anti-tumor activity of alpha-interferon for renal cell carcinoma, especially in autoptic cases].
    Yamauchi T, Kawamura J, Yoshida O, Fukuyama T, Ogura K, Nakagawa K.
    Hinyokika Kiyo; 1985 Sep 15; 31(9):1539-52. PubMed ID: 4083212
    [Abstract] [Full Text] [Related]

  • 19. The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit.
    Grossberg SE, Kawade Y, Kohase M, Klein JP.
    J Interferon Cytokine Res; 2001 Sep 15; 21(9):743-55. PubMed ID: 11576468
    [Abstract] [Full Text] [Related]

  • 20. Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies.
    Steis RG, Smith JW, Urba WJ, Clark JW, Itri LM, Evans LM, Schoenberger C, Longo DL.
    N Engl J Med; 1988 Jun 02; 318(22):1409-13. PubMed ID: 3367950
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.